MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

Начало・Списък с акции・Quest Diagnostics Inc

Quest Diagnostics Inc

Затворен

СекторЗдравеопазване

195.9 -0.6

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

192.32

Максимум

197.7

Ключови измерители
By Trading Economics
Приходи	-14M 245M
Продажби	-10M 2.8B
P/E Средно за сектора	22.354 57.05
Дивидентна доходност	1.64
Марж на печалбата	8.731
Служители	46,000
EBITDA	-146M 401M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+12.15% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	1.64% 2.52%
Следващи печалби	21.04.2026 г.
Следваща дата на дивидент	20.04.2026 г.
Следваща дата на екс-дивидент	6.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	373M 22B
Предишно отваряне	196.5
Предишно затваряне	195.9

Настроения в новините

By Acuity

24%

76%

69 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

175.87 / 176.5 Подкрепа & съпротива

Quest Diagnostics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.03.2026 г., 23:31 ч. UTC

Горещи акции

Stocks to Watch: Nike, RH, NCino

31.03.2026 г., 22:35 ч. UTC

Печалби

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1.04.2026 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31.03.2026 г., 23:50 ч. UTC

Придобивния, сливания и поглъщания

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31.03.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31.03.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31.03.2026 г., 23:21 ч. UTC

Печалби

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31.03.2026 г., 23:14 ч. UTC

Пазарно говорене

Печалби

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31.03.2026 г., 23:12 ч. UTC

Пазарно говорене

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Loss Widens >000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31.03.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31.03.2026 г., 21:36 ч. UTC

Пазарно говорене

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Expects China Sales Down 20% in 4Q, CFO Says

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31.03.2026 г., 21:33 ч. UTC

Печалби

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31.03.2026 г., 21:32 ч. UTC

Печалби

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31.03.2026 г., 21:28 ч. UTC

Печалби

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31.03.2026 г., 21:26 ч. UTC

Печалби

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31.03.2026 г., 21:25 ч. UTC

Печалби

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31.03.2026 г., 21:24 ч. UTC

Пазарно говорене

Печалби

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31.03.2026 г., 21:22 ч. UTC

Печалби

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31.03.2026 г., 21:22 ч. UTC

Печалби

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31.03.2026 г., 21:21 ч. UTC

Печалби

Nike's Digital Channel Still Too Promotional, CFO Says

31.03.2026 г., 21:20 ч. UTC

Печалби

Nike CEO: Converse Remains Important to Portfolio

Сравнение с други в отрасъла

Ценова промяна

Quest Diagnostics Inc Прогноза

Ценова цел

By TipRanks

12.15% нагоре

12-месечна прогноза

Среден 221.11 USD 12.15%

Висок 235 USD

Нисък 210 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Quest Diagnostics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Quest Diagnostics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

175.87 / 176.5Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

69 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Quest Diagnostics Inc

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.